Tag Archives: deflazacort

March, 2017

17 March
PTC Therapeutics Acquires Marathon Pharma’s DMD Drug Emflaza for $140 Million

SOUTH PLAINFIELD, N.J., March 16, 2017 /PRNewswire/ — PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced it has entered into an asset purchase agreement with Marathon Pharmaceuticals, LLC to acquire all rights to Emflaza™ (deflazacort). Emflaza is the first treatment approved in the United States for all Duchenne muscular dystrophy (DMD) patients …
Share

9 February
FDA Approves Marathon’s Emflaza for Treatment of Duchenne Muscular Dystrophy

The U.S. Food and Drug Administration today approved Emflaza (deflazacort) tablets and oral suspension to treat patients age 5 years and older with Duchenne muscular dystrophy (DMD), a rare genetic disorder that causes progressive muscle deterioration and weakness. Emflaza is a corticosteroid that works by decreasing inflammation and reducing the …
Share

15 June
Marathon Seeks FDA Approval for its Duchenne Muscular Dystrophy Drug

NORTHBROOK, Ill.–(BUSINESS WIRE)–Marathon Pharmaceuticals, LLC, a biopharmaceutical company developing treatments for rare diseases, today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the investigational drug deflazacort for the treatment of patients with Duchenne muscular dystrophy (DMD), the most common and …
Share

9 March
Marathon Pharmaceuticals Announces Nationwide Expanded Access Program for DMD Patients

NORTHBROOK, Ill., March 9, 2016 /PRNewswire-USNewswire/ — Marathon Pharmaceuticals, a leader in developing treatments for rare diseases, announced today that it is expanding patient access to deflazacort, its investigational medicine for Duchenne Muscular Dystrophy (DMD). Through Marathon’s ACCESS DMD™ program, deflazacort is now being made available to qualified patients, at no cost, …
Share